Dante Labs commits to ending Rare Disease Odysseys globally through Stripe2be: a patient-centric whole genome based solution tailored for rare disease patients
July 08, 2021 04:00 ET | Dante Labs
Stripe2be uses an unbiased approach to Whole Genome Sequencing (WGS) for rare diseases: combining the information submitted from both personal patient records and statements, and using the Dante Labs...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
May 18, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 10:30 ET | Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
May 15, 2020 07:30 ET | Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
May 04, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
April 30, 2020 13:31 ET | Seelos Therapeutics, Inc.
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 19, 2020 08:02 ET | Seelos Therapeutics, Inc.
Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
February 13, 2020 16:30 ET | Seelos Therapeutics, Inc.
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
REZOLUTE.jpg
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
February 10, 2020 08:30 ET | Rezolute, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical...
REZOLUTE.jpg
Rezolute to Present at BIO CEO & Investor Conference 2020
January 27, 2020 08:30 ET | Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical...